Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Merck Serono, Flamel Ink Bio-Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Merck Serono, Flamel Ink Bio-Pact

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck Serono and Flamel Technologies have entered into a collaboration to investigate the applicability of Flamel’s Medusa technology for the extended release of a therapeutic protein of Merck Serono’s portfolio. Merck Serono will make an upfront payment of $2.8 million to Flamel for investigating the therapeutic protein and will fund R&D efforts performed by Flamel. Financial terms, including a license agreement to cover potential commercialization, were not disclosed.

“We are delighted to enter into this partnership with Flamel, as it gives Merck Serono access to a technology that may further improve the therapeutic potential of compounds in our portfolio,” said Bernhard Kirschbaum, Merck Serono’s head of research. “As Flamel’s Medusa technology allows for longer intervals between administrations of injectable proteins compared to standard formulations, we hope to offer an improved convenience for patients requiring treatment by injection. As a consequence, we anticipate that employing this technology will lead to better treatment outcomes for patients.”

Stephen H. Willard, Flamel’s chief executive officer, remarked, “We are pleased to have reached an agreement with Merck Serono. The Medusa platform is a best-in-class technology for the controlled delivery of proteins, peptides, and other molecules. This applicability to a wide range of molecules is a key strength of the platform, as is the ability to sustain release without affecting bioactivity. Merck Serono is the ideal partner for this project and we look forward to working together on such an exciting opportunity.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters